We're increasingly climbing the automation curve of just industrial outomation, doesn't ned to be lab automatic. Is there something out there that could become a massive accelerate in this whole space? And like even like, did that dana sequencer that alumina has that, you know, or like oxford nano pour out in the ucades,. Like, do these cheap genoms? Wellno, herno hers up, et cetera.
First Jason explains how to deliver great investor updates & the benefits of doing them well (1:36). Then, Ginkgo Bioworks CEO Jason Kelly joins to discuss the expanding capabilities of synthetic biology (24:48), how Ginkgo is currently helping customers make products more effectively (35:58), the ethics & risks of editing DNA (51:53) & more!